Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.602NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.602NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.602NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.289NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.289NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.289NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
DV.7.1.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.7.1.6NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DV.7.1.6NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XDHNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDHNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XDHNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FL.15.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.15.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.15.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
EG.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.2.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EG.2.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.16.32NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.16.32NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.16.32NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.273NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.273NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.273NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.13 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.13 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.13 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.358NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.358NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.358NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
C.28NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.28NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.28NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.60NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.60NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.60NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.159NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.159NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.159NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.29NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.29NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.510NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.510NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.510NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.91NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.91NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.91NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.227NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.227NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used